Graphite Bio Announces Participation in Upcoming September Investor Conferences
08/30/2021 - 08:00 AM
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that members of the management team will participate in virtual fireside chats at the following investor conferences:
Morgan Stanley 19th Annual Global Healthcare Conference on Monday, Sept. 13, 2021 , at 2:45 p.m. ET ; and
2021 Cantor Virtual Global Healthcare Conference on Monday, Sept. 27, 2021 , at 2:40 p.m. ET .
The fireside chats will be webcast live from Graphite Bio’s website at www.graphitebio.com in the Investors section. Replays of the webcasts will be archived and available for one month following each event.
About Graphite Bio
Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus , M.D., Ph.D.
View source version on businesswire.com : https://www.businesswire.com/news/home/20210830005113/en/
Company Contact:
Stephanie Yao
VP, Communications and Investor Relations
443-739-1423
syao@graphitebio.com
Investor Relations:
Stephanie Ascher
Stern IR, Inc.
212-362-1200
ir@graphitebio.com
Media Contact:
Christy Curran
Sam Brown, Inc.
615-414-8668
media@graphitebio.com
Source: Graphite Bio, Inc.
GRPH Rankings
#4009 Ranked by Stock Gains
GRPH Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Electronics Distributors
About GRPH
graphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process of homology directed repair (hdr) and targeted dna integration to precisely repair genetic defects at their source. graphite bio is leveraging its differentiated platform to advance a portfolio of transformative genetic treatments with potential for saving and dramatically improving patients’ lives